Lv7
4410 积分 2024-03-11 加入
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
11天前
已完结
Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis
1个月前
已完结
Investigating the origins of recent pharmaceutical innovation
3个月前
已完结
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
4个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
5个月前
已完结
Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis
5个月前
已完结
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial
7个月前
已完结
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
8个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
8个月前
已完结
皖公网安备34019202002308
